title: Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials.
abstract: We performed a systematic review and meta-analysis to assess the potential of erlotinib plus platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced non-small-cell lung cancer (NSCLC). Search of PubMed, EMBASE, Web of Science, CBM, CNKI, China Wan Fang databases and the Cochrane library was performed for studies regarding erlotinib plus platinum-based chemotherapy for advanced NSCLC published between 1 January 2000 and 28 August 2014. We identified eight eligible studies including 3,363 patients with advanced NSCLC. For PFS measure, an HR of 0.73 (0.58-0.93) with statistical significance was estimated when erlotinib plus platinum-based chemotherapy compared with platinum-based chemotherapy alone; objective response rate of 32.86 versus 24.85 % was obtained for both groups, respectively. HR of 0.93 (0.86-1.00) with P of 0.170 was calculated for OS. We concluded that the erlotinib plus chemotherapy for advanced NSCLC could increase PFS and objective response rate, but not benefit OS.
authors.affiliation: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, 149 Dalian Road, Zunyi, 563000, China, jianguo.zhou@yahoo.com.
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Zhou
authors.forename: Xu
authors.initials: X
authors.lastname: Tian
authors.forename: Xue
authors.initials: X
authors.lastname: Wang
authors.forename: Jin-Hui
authors.initials: JH
authors.lastname: Tian
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
authors.forename: Fei
authors.initials: F
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Hu
authors.initials: H
authors.lastname: Ma
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D017671:Platinum Compounds / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*
chemical_list: D017671:Platinum Compounds; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride